An interventional study of Time-restricted eating in Metabolically Healthy Obesity and Intermittent Fasting, sponsored by Instituto de Nutrición y Tecnología de los Alimentos. Completed at 1 site in Chile. Open to male participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Instituto de Nutrición y Tecnología de los Alimentos · Not applicable, Interventional, and Treatment
Obesity-related cardiometabolic diseases are now a leading cause of death worldwide. These diseases result from a dysfunctional adipose tissue (AT) that induces inflammation, insulin resistance and altered endocrine function. However, not all obese people develop metabolic complications, which has given rise to the concept of "metabolically healthy obesity" (MHO). Recent evidence suggests that intermittent fasting methods, in particular time-restricted eating (TRE) may be effective in improving cardiometabolic health, independently of weight loss, and this could be particularly effective in MUO subjects. The investigators hypothesize that in young male adults TRE is a more effective/beneficial approach in MUO than in MHO due to the weight loss-independent improvement in their inflammatory and metabolic derangements. To this aim, a 16-week 8h TRE intervention study will be performed in MHO and MUO subjects, assessing anthropometric, endocrine, and other outcomes.
Although clinical differences between metabolically healthy and unhealthy obesity (MHO and MUO, respectively) have been extensively described, cellular mechanisms involved in these different phenotypes are largely unknown. This evidence is crucial for proposing preventive and therapeutic approaches. Recently, intermittent fasting methods, in particular time-restricted eating (TRE, a self-selected daily limited eating window protocol), have shown to be effective in improving cardiometabolic health, independently of weight loss, which could be particularly relevant in MUO.
The investigators will recruit young (20-22y-old) males with obesity (Body Mass Index≥30) and classify them as MHO or MUO (≤1 or ≥3 metabolic syndrome risk factors, respectively). A 16-week, 8h TRE intervention will be conducted in MHO vs. MUO subgroups, to assess and compare the anthropometric, metabolic, endocrine, inflammatory and peripheral blood mononuclear cell (PBMC) mechanistic/signaling response.
The investigators expect to advance the understanding of cellular mechanisms implicated in MHO and MUO, including potential therapeutic targets. Ultimately, the investigators expect to find relevant opportunities for intervention to prevent the serious cardiometabolic consequences of obesity.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 53 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Instituto de Nutrición y Tecnología de los Alimentos is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
metabolically healthy obese subjects undergoing TRE
Behavioral: Time-restricted eating
metabolically unhealthy obese subjects undergoing TRE
Behavioral: Time-restricted eating
16 weeks of TRE consisting of an 8-hour eating window.
Also known as: Time-restricted feeding, Intermittent fasting
TG
Fasting triglycerides
Time frame: 16 weeks
Waist circumference
Time frame: 16 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Nutrición y Tecnología de los Alimentos